SEC Form 424B3 filed by CERo Therapeutics Holdings Inc.
$CERO
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Unavailable
Unavailable
Save time and jump to the most important pieces.
Company continues toward the initiation of its Phase 1 Clinical Trial in AML for CER-1236 SOUTH SAN FRANSCISCO, Calif., March 06, 2025 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc., (NASDAQ:CERO) ("CERo" or the "Company") an innovative immunotherapy company seeking to advance the next generation of engineered T cell therapeutics that employ phagocytic mechanisms, announces the execution of an agreement with contract research organization (CRO) CellCarta to manage translational assays for the Company's upcoming Phase 1 clinical trial of CER-1236 for Acute Myeloid Leukemia (AML). This is important progress as the Company prepares to enroll patients in the trial, as CellCarta will be
New poster to highlight preclinical data of CER-1236 in ovarian cancer SOUTH SAN FRANSCISCO, Calif., March 05, 2025 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc., (NASDAQ:CERO) ("CERo" or the "Company") an innovative immunotherapy company seeking to advance the next generation of engineered T cell therapeutics that employ phagocytic mechanisms, announces it will be presenting preclinical results of lead compound CER-1236 in ovarian cancer during the Spring Scientific from the Society for Immunotherapy of Cancer (SITC) in San Diego, March 12-14. The poster, titled, "TIM-4-L Expression on Ovarian Cancer Samples can be Targeted by Engineered Chimeric Engulfment Receptor T cells with
Increased cash balance and momentum with both Nasdaq and Phase 1 trial initiation mark strong beginning for 2025 SOUTH SAN FRANSCISCO, Calif., Feb. 06, 2025 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc., (NASDAQ:CERO) ("CERo" or the "Company") an innovative immunotherapy company seeking to advance the next generation of engineered T cell therapeutics that employ phagocytic mechanisms, provides investors with a corporate update highlighting its improved cash balance following its recent capital raise, steady progress in the initiation of its Phase 1 clinical trial of CER-1236, and a pathway toward maintaining Nasdaq listing. CEO Chris Ehrlich commented, "We have had a very strong e
424B3 - CERO THERAPEUTICS HOLDINGS, INC. (0001870404) (Filer)
424B3 - CERO THERAPEUTICS HOLDINGS, INC. (0001870404) (Filer)
424B3 - CERO THERAPEUTICS HOLDINGS, INC. (0001870404) (Filer)
4 - CERO THERAPEUTICS HOLDINGS, INC. (0001870404) (Issuer)
4 - CERO THERAPEUTICS HOLDINGS, INC. (0001870404) (Issuer)
4 - CERO THERAPEUTICS HOLDINGS, INC. (0001870404) (Issuer)
SC 13G - CERO THERAPEUTICS HOLDINGS, INC. (0001870404) (Subject)
SC 13G/A - CERO THERAPEUTICS HOLDINGS, INC. (0001870404) (Subject)
SC 13G - CERO THERAPEUTICS HOLDINGS, INC. (0001870404) (Subject)
SOUTH SAN FRANCISCO, Calif, Dec. 06, 2024 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc. (NASDAQ:CERO) ("CERo"), an innovative immunotherapy company seeking to advance the next generation of engineered T cell therapeutics augmented with phagocytic mechanisms derived from the innate arm of the immune system, announces its Board of Directors has appointed Chris Ehrlich as CEO. Previously he held the position of Interim CEO. Mr. Ehrlich commented, "I believe that CERo presents multiple, significant opportunities to make an impact on the market and benefit a significant patient population with both sound science and an experienced team of professionals to drive successful execution.